Rottendorf Pharmaceuticals Signs Multiple New Deals

Rottendorf Pharmaceuticals, the US-based subsidiary of German company Rottendorf Pharma, signed in the last quarter three formulation development projects and two commercial transfer projects with multiple top 5 pharmaceutical and biopharmaceutical companies.

"The new projects signed in the last quarter reflect the industry's positive response to our business model and our commitment to Total Process Ownership (TPO)," said Rottendorf Pharmaceuticals CEO Gordon Haines. "TPO relies on open communication and exchange of ideas with our pharma partners and draws on 85 years of formulation development and manufacturing experience to recommend process optimizations to ultimately produce a better end product."

"We are owned by a charitable foundation, which allows us to focus more on long-term success of our business and the goals of our customers, rather than needing to satisfy shareholders on a quarter-by-quarter basis," Haines added.

Recently Rottendorf won five separate 2015 CMO Leadership Awards presented by Life Science Connect. The awards are based on survey results of more than 65,000 questionnaires sent to a broad range of both pharma and biotech companies.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
06.03.2025 • News

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.